Please login to the form below

Not currently logged in
Email:
Password:

ABT-450

This page shows the latest ABT-450 news and features for those working in and with pharma, biotech and healthcare.

AbbVie closes in on US approval of all-oral hepatitis C regimen

FDA grants priority review to company’ s protease inhibitor ABT-450 regimen. ... The regimen consists of the protease inhibitor ABT-450 boosted by ritonavir and co-formulated with the polymerase inhibitor dasabuvir, alongside NS5A inhibitor ombitasvir,

Latest news

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest from PMHub

  • Warehousing of HCV patients reaches new high

    However, Abbvie’ s products ABT 267, ABT 333 and ABT 450 remain contenders for market share, scoring higher than J&J’ s simeprevir in terms of likelihood to prescribe amongst doctors

  • Warehousing of HCV patients reaches new high

    However, Abbvie’ s products ABT 267, ABT 333 and ABT 450 remain contenders for market share, scoring higher than J&J’ s simeprevir in terms of likelihood to prescribe amongst doctors

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics